TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

NCT03952091 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

289

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma in Relapse
Refractory Multiple Myeloma

Interventions

DRUG: TJ202, Lenalidomide and Dexamethasone
DRUG: Lenalidomide and Dexamethasone

Sponsor

TJ Biopharma Co., Ltd.